Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.29 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 5.87 billion
Earnings per share -0.005
Dividend per share N/A
Year To Date Return -51.25%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Imugene Ltd (ASX: IMU)
Latest News

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Share Market News

ASX 200 midday update: Regis Resources jump, big four banks fall ahead of RBA meeting

The ASX 200 is on form again on Tuesday...

Read more »

Red arrow going down, symbolising a falling share price.
Share Fallers

Why Carsales, EOS, Imugene, and Tyro shares are sinking today

These ASX shares are sinking on Wednesday...

Read more »

A man is deep in thought while looking at graph and rising and falling percentages.
Share Market News

ASX 200 midday update: Carsales sinks, Liontown jumps on Ford agreements

The ASX 200 is having a disappointing day on Wednesday...

Read more »

Group of stressful businesspeople having problems. sittong around a desk.
Share Fallers

Why Appen, BWX, Imugene, and Wesfarmers shares are dropping

These ASX shares are dropping into the red today...

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Share Market News

ASX 200 midday update: Tech shares tumble, Collins Foods jumps

Here's what is happening on the ASX 200 on Tuesday...

Read more »

Share Market News

Here are the 3 most heavily traded ASX 200 shares on Monday

We take a look at the most traded ASX 200 shares by volume today.

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why Imugene, Link, Metcash, and Sayona shares are racing higher

These ASX shares are racing higher on Monday...

Read more »

Happy healthcare workers in a labs
Healthcare Shares

‘Significant milestone’: Why the Imugene share price is soaring 30% today

What's driving the Imugene share price higher today?

Read more »

IMU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Imugene Ltd

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

IMU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
04 Jul 2022 $0.22 $0.03 15.38% 21,165,116 $0.21 $0.23 $0.20
01 Jul 2022 $0.20 $0.02 11.11% 20,200,371 $0.19 $0.21 $0.18
30 Jun 2022 $0.18 $-0.01 -5.41% 20,079,224 $0.19 $0.20 $0.18
29 Jun 2022 $0.19 $-0.03 -13.95% 37,159,504 $0.21 $0.21 $0.18
28 Jun 2022 $0.22 $-0.03 -12.50% 42,609,870 $0.25 $0.25 $0.21
27 Jun 2022 $0.24 $0.08 48.48% 109,344,947 $0.19 $0.25 $0.18
24 Jun 2022 $0.17 $0.03 21.43% 23,578,091 $0.14 $0.17 $0.14
23 Jun 2022 $0.14 $0.00 0.00% 23,341,885 $0.15 $0.15 $0.14
22 Jun 2022 $0.15 $-0.02 -12.50% 14,168,644 $0.17 $0.17 $0.15
21 Jun 2022 $0.16 $0.01 6.67% 18,744,355 $0.16 $0.17 $0.15
20 Jun 2022 $0.15 $0.01 7.14% 15,165,049 $0.14 $0.16 $0.14
17 Jun 2022 $0.14 $0.00 0.00% 21,578,978 $0.14 $0.15 $0.14
16 Jun 2022 $0.15 $0.00 0.00% 16,299,133 $0.14 $0.15 $0.14
15 Jun 2022 $0.14 $0.00 0.00% 18,995,659 $0.14 $0.15 $0.14
14 Jun 2022 $0.14 $-0.01 -6.67% 31,879,859 $0.14 $0.15 $0.13
10 Jun 2022 $0.15 $0.00 0.00% 18,863,761 $0.15 $0.16 $0.15
09 Jun 2022 $0.15 $-0.01 -6.25% 24,772,114 $0.16 $0.16 $0.15
08 Jun 2022 $0.16 $-0.01 -6.06% 16,186,881 $0.17 $0.17 $0.16
07 Jun 2022 $0.17 $-0.01 -5.88% 14,233,037 $0.17 $0.17 $0.16

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Jun 2022 Charles Walker Buy 128 $19,840
On-market trade.
07 Jun 2022 Lesley Russell Buy 10 $450,000
Exercise of options.
07 Jun 2022 Lesley Russell Exercise 10 $450,000
As advised by the company.
07 Jun 2022 Lesley Russell Transfer 500 $82,500
Off-market transfer. Assuming off-market transfer of shares from direct to indirect
07 Jun 2022 Lesley Russell Transfer 500 $82,500
Off-market transfer. Assuming off-market transfer of shares from direct to indirect
07 Feb 2022 Jens Eckstein Sell 2 $630,000
On-market trade.
07 Feb 2022 Jens Eckstein Exercise 15 $620,000
Exercise of options.
07 Feb 2022 Jens Eckstein Buy 15 $620,000
Exercise of options.
13 Dec 2021 Paul Hopper Sell 1 $611,961
On-market trade.
13 Dec 2021 Paul Hopper Sell 73 $36,138,039
On-market trade.
17 Nov 2021 Axel Hoos Sell 10 $5,650,000
On-market trade. Average price
16 Nov 2021 Axel Hoos Exercise 10 $450,000
Exercise of options.
16 Nov 2021 Axel Hoos Buy 10 $450,000
Exercise of options.
22 Oct 2021 Paul Hopper Issued 99 $1,545,142
Issue of securities.
22 Oct 2021 Paul Hopper Issued 1 $19,353
Issue of securities.
06 Oct 2021 Lesley Russell Sell 3 $1,360,000
On-market trade.
09 Sep 2021 Paul Hopper Issued 1 $17,205
Issue of securities.
09 Sep 2021 Paul Hopper Issued 88 $1,373,624
Issue of securities.
20 Aug 2021 Charles Walker Sell 7 $4,011,513
On-market trade.
20 Aug 2021 Charles Walker Sell 106 $55,742
On-market trade.
20 Aug 2021 Charles Walker Buy 13 $4,001
Participation in share purchase plan.
20 Aug 2021 Charles Walker Buy 6 $1,900
Participation in share purchase plan. As per announcement on 20/12/2021

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
Ms Chong joined the group in September 2015 from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 23 years' experience in leading clinical and department development in oncology. In November 2016, Ms Chong was promoted as Imugene's CEO and joined the board as Managing Director in March 2018. Her other current directorships are Chimeric Therapeutics (ASX: CHM), since 28 August 2020 Cure Brain Cancer Foundation (non-profit organisation), since April 2020
Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Other current directorships held by him are at Radiopharm Theranostics Limited, since 11 February 2021 Chimeric Therapeutics Limited (ASX: CHM), since 2 February 2020 Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), since December 2020 SUDA Pharmaceuticals Ltd (ASX: SUD), since 15 May 2019
Mr Charles Walker Non-Executive Director Jan 2015
Mr Walker has experience across the biotechnology and life sciences industry. His experience includes operational and leadership positions in biotechnology firms, a strong capital markets track record from executing nearly 60 international and domestic corporate transactions, both as principal and advisor, and a detailed scientific understanding gained from a technical background in pharmacology. Mr Walker was previously Chief Executive Officer and Chief Financial Officer of Alchemia Limited (ASX: ACL) and Managing Director of Imugene.
Dr Lesley Russell Non-Executive Director Apr 2019
Dr Russell is a haematologist/oncologist and has over 25 years' experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships held by her are Chimeric Therapeutics Limited (ASX: CHM), since 28 August 2020 Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016 Former directorships in last 3 years held by her are Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), until March 2021 AMAG Pharma (NASDAQ: AMAG), until May 2019 Endocyte Pharmaceuticals (NASDAQ: ECYT), until December 2018
Dr Jens Eckstein Non-Executive Director May 2019
Dr Eckstein has more than 15 years' venture capital experience in the biopharmaceutical industry and 10 years' operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Other current directorships held by him are Aeovian Pharmaceuticals (USA, private) Samsara Therapeutics (UK, private) Cleara Biotech (The Netherlands, private) HAYA Therapeutics (Switzerland, private) BosWell (USA, private) Former directorships in last 3 years held by him are Gladius Pharmaceuticals (Canada, private) Decibel Therapeutics (NASDAQ:DBTX) Palleon Pharmaceuticals (USA, private) ZappRx (USA, private)
Mr Nathan Jong Joint Company Secretary Dec 2021
-
Mr Phillip Hains Chief Financial OfficerJoint Company Secretary Dec 2012
-
Phillip Hains Chief Financial OfficerJoint Company Secretary
-
Dr Rita Laeufle Chief Medical Officer
-
Dr Nicholas Ede Chief Technology Officer
-
Nathan Jong Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 325,090,826 5.96%
Mann Family 292,046,995 5.35%
Paul Hopper 291,196,435 5.34%
HSBC Custody Nominees (Australia) Limited 182,739,184 3.35%
Dr Nicholas Smith 118,000,000 2.16%
J P Morgan Nominees Australia Pty Limited 105,218,342 1.93%
Mi Ok Chong 77,000,000 1.41%
National Nominees Limited 72,967,954 1.34%
Sarah Cameron 60,000,000 1.10%
Netwealth Investments Limited <Wrap Services A/C> 59,066,565 1.08%
Ubs Nominees Pty Ltd 45,686,667 0.84%
Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> 40,327,647 0.74%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 40,271,895 0.74%
Est Mr Andrew John Kempson 34,921,053 0.64%
Dr Yuman Fong 33,312,301 0.61%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 30,717,078 0.56%
Mr Andrew Murray Gregor 30,298,830 0.56%
Dr Axel Hoos 23,375,000 0.43%

Profile

since

Note